Inactive Instrument

Highlights Aralez Pharmaceuticals Inc Nasdaq

Equities

CA03852X1006

Highlights

Unlock all the news: Be the first to know and act before the market!

Nuvo Pharmaceuticals Inc. completed the acquisition of Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc..	31/18/31	CI
Nuvo Pharmaceuticals Inc. signed a letter of intent to acquire Aralez Pharmaceuticals Canada Inc. from Aralez Pharmaceuticals Inc. for $62.5 million.	10/18/10	CI
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	08/18/08	CI
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2017; Provides Earnings Guidance for the Fiscal Year 2018	13/18/13	CI
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017; Revises Earnings Guidance for the Year Ending December 31, 2017 and provides Preliminary Guidance for Full Year Ending December 31, 2018	09/17/09	CI
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Revises Earnings Guidance for the Full Year 2017	09/17/09	CI
Aralez Pharmaceuticals Inc. Announces National Commercial Launch of Zontivity in US	07/17/07	CI
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Updates Earnings Guidance for the Year Ending December 31, 2017	09/17/09	CI
Aralez Mulls Acquisitions	20/17/20	CI
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016; Provides Earnings Guidance for the Year Ending December 31, 2017; Reports Impairment Charges for the Fourth Quarter of 2016	13/17/13	CI
Aralez Pharmaceuticals Inc. Unveils New Office in Ireland	02/17/02	CI
Aralez Announces Commercial Launch of BLEXTEN in Canada	19/16/19	CI
Aralez Pharmaceuticals Inc. Enters into Rebate Agreement with CaremarkPCS Health	15/16/15	CI
Aralez Pharmaceuticals Inc. Announced New Data for YOSPRALA™	14/16/14	CI
Aralez Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016; Revises Revenue Guidance for the Full Year Ending December 31, 2016	07/16/07	CI
Aralez Pharmaceuticals Mulls Acquisitions	04/16/04	CI
Aralez Pharmaceuticals Inc. Announces the Availability of Once-Daily YOSPRALA™	03/16/03	CI
Aralez Announces FDA Approval of YOSPRALA™ for Secondary Prevention of Cardiovascular and Cerebrovascular Events in Patients at Risk for Aspirin-Associated Gastric Ulcers	15/16/15	CI
Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	09/16/09	CI
Aralez Pharmaceuticals Mulls Acquisitions	09/16/09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aralez Pharmaceuticals Inc Nasdaq

Equities

CA03852X1006

Highlights

Filters